Top

Diabetologia

Published in:

01-05-2009 | Article

Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population

Authors: Q. Qi, Y. Wu, H. Li, R. J. F. Loos, F. B. Hu, L. Sun, L. Lu, A. Pan, C. Liu, H. Wu, L. Chen, Z. Yu, X. Lin

Published in: Diabetologia | Issue 5/2009

Abstract

Aims/hypothesis

The GCKR rs780094 and GCK rs1799884 polymorphisms have been reported to be associated with dyslipidaemia and type 2 diabetes in white Europeans. The aim of this study was to replicate these associations in Han Chinese individuals and to identify the potential mechanisms underlying these associations.

Methods

The single nucleotide polymorphisms rs780094 and rs1799884 were genotyped in a population-based sample of Han Chinese individuals (n = 3,210) and tested for association with risk of type 2 diabetes and related phenotypes.

Results

The GCKR rs780094 A allele was marginally associated with reduced risk of type 2 diabetes (OR 0.85, 95% CI 0.73–1.00, p value under an additive model [p _(add)] = 0.05) and significantly associated with reduced risk of impaired fasting glucose (IFG) or type 2 diabetes (OR 0.86, 95% CI 0.77–0.96, p _[add] = 0.0032). It was also significantly associated with decreased fasting glucose and increased HOMA of beta cell function (HOMA-B) and fasting triacylglycerol levels (p _[add] = 0.0169–5.3 × 10⁻⁶), but not with HOMA of insulin sensitivity (HOMA-S). The associations with type 2 diabetes and IFG remained significant after adjustment for BMI, while adjustment for HOMA-B abolished the associations. The GCKR rs780094 was also associated with obesity and BMI, independently of its association with type 2 diabetes. The GCK rs1799884 A allele was significantly associated with decreased HOMA-B (p _[add] = 0.0005), but not with type 2 diabetes or IFG. Individuals with increasing numbers of risk alleles for both variants had significantly lower HOMA-B (p _[add] = 5.8 × 10⁻⁵) in the combined analysis.

Conclusions/interpretation

Consistent with observations in white Europeans, the GCKR rs780094 polymorphism contributes to the risk of type 2 diabetes and dyslipidaemia in Han Chinese individuals. In addition, we showed that the effect on type 2 diabetes is probably mediated through impaired beta cell function rather than through obesity.

Available only for authorised users

Matschinsky FM (1996) Banting lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45:223–241PubMedCrossRef

Froguel P, Zouali H, Vionnet N et al (1993) Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 328:697–702PubMedCrossRef

Gloyn AL (2003) Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 22:353–362PubMedCrossRef

Njolstad PR, Sovik O, Cuesta-Munoz A et al (2001) Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 344:1588–1592PubMedCrossRef

Christesen HB, Jacobsen BB, Odili S et al (2002) The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 51:1240–1246PubMedCrossRef

Cuesta-Munoz AL, Huopio H, Otonkoski T et al (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53:2164–2168PubMedCrossRef

Glaser B, Kesavan P, Heyman M et al (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338:226–230PubMedCrossRef

Gloyn AL, Noordam K, Willemsen MA et al (2003) Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52:2433–2440PubMedCrossRef

Vaxillaire M, Veslot J, Dina C et al (2008) Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 57:244–254PubMedCrossRef

10.

Marz W, Nauck M, Hoffmann MM et al (2004) G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus. Circulation 109:2844–2849PubMedCrossRef

11.

Rose CS, Ek J, Urhammer SA et al (2005) A -30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. Diabetes 54:3026–3031PubMedCrossRef

12.

Stone LM, Kahn SE, Fujimoto WY, Deeb SS, Porte D Jr (1996) A variation at position −30 of the beta-cell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men. Diabetes 45:422–428PubMedCrossRef

13.

Yamada K, Yuan X, Ishiyama S et al (1997) Clinical characteristics of Japanese men with glucokinase gene beta-cell promoter variant. Diabetes Care 20:1159–1161PubMedCrossRef

14.

Chu CA, Fujimoto Y, Igawa K et al (2004) Rapid translocation of hepatic glucokinase in response to intraduodenal glucose infusion and changes in plasma glucose and insulin in conscious rats. Am J Physiol Gastrointest Liver Physiol 286:G627–G634PubMedCrossRef

15.

Farrelly D, Brown KS, Tieman A et al (1999) Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci U S A 96:14511–14516PubMedCrossRef

16.

Slosberg ED, Desai UJ, Fanelli B et al (2001) Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein. Diabetes 50:1813–1820PubMedCrossRef

17.

Comuzzie AG, Hixson JE, Almasy L et al (1997) A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. Nat Genet 15:273–276PubMedCrossRef

18.

Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef

19.

Sparso T, Andersen G, Nielsen T et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75PubMedCrossRef

20.

Vaxillaire M, Cavalcanti-Proenca C, Dechaume A et al (2008) The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 57:2253–2257PubMedCrossRef

21.

Koster B, Fenger M, Poulsen P, Vaag A, Bentzen J (2005) Novel polymorphisms in the GCKR gene and their influence on glucose and insulin levels in a Danish twin population. Diabet Med 22:1677–1682PubMedCrossRef

22.

Orho-Melander M, Melander O, Guiducci C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121PubMedCrossRef

23.

Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X (2007) Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol 49:1798–1805PubMedCrossRef

24.

Wu Y, Li H, Loos RJ et al (2008) Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes 57:2834–2842PubMedCrossRef

25.

Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192PubMedCrossRef

26.

Bei-Fan Z (2002) Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Asia Pac J Clin Nutr 11(Suppl 8):S685–S693PubMedCrossRef

27.

O’Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB (1999) Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidaemia. Diabetes 48:2022–2027PubMedCrossRef

28.

Cauchi S, Nead KT, Choquet H et al (2008) The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. BMC Med Genet 9:45PubMedCrossRef

29.

Alvarez E, Roncero I, Chowen JA, Vazquez P, Blazquez E (2002) Evidence that glucokinase regulatory protein is expressed and interacts with glucokinase in rat brain. J Neurochem 80:45–53PubMedCrossRef

30.

Lynch RM, Tompkins LS, Brooks HL, Dunn-Meynell AA, Levin BE (2000) Localization of glucokinase gene expression in the rat brain. Diabetes 49:693–700PubMedCrossRef

31.

Yang XJ, Mastaitis J, Mizuno T, Mobbs CV (2007) Glucokinase regulates reproductive function, glucocorticoid secretion, food intake, and hypothalamic gene expression. Endocrinology 148:1928–1932PubMedCrossRef

32.

Gomez-Zumaquero JM, Rojo-Martinez G, Garcia-Escobar E et al (2008) The -30G>A polymorphism of the glucokinase gene promoter is associated with obesity in a population from southern Spain. Obesity (Silver Spring) 16:1973–1975CrossRef

33.

Yamada Y, Kato K, Kameyama T et al (2006) Genetic factors for obesity. Int J Mol Med 18:843–851PubMed

34.

Lotfi K, Sund G, Lowe R et al (1997) The beta cell glucokinase promoter variant is an unlikely risk factor for diabetes mellitus. Diabetes Incidence Study in Sweden (DISS). Diabetologia 40:959–962PubMedCrossRef

35.

Shimokawa K, Sakura H, Otabe S et al (1994) Analysis of the glucokinase gene promoter in Japanese subjects with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79:883–886PubMedCrossRef

36.

Ridker PM, Pare G, Parker A et al (2008) Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet 82:1185–1192PubMedCrossRef

37.

Postic C, Shiota M, Niswender KD et al (1999) Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:305–315PubMedCrossRef

Title: Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population
Authors: Q. Qi
Y. Wu
H. Li
R. J. F. Loos
F. B. Hu
L. Sun
L. Lu
A. Pan
C. Liu
H. Wu
L. Chen
Z. Yu
X. Lin
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 5/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1290-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 5/2009

Glucose allostasis: Disrobing common wisdom

Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study

Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice

Inhibition of the chemokine (C–C motif) ligand 2/chemokine (C–C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy

Prevention of neural tube defects by loss of function of inducible nitric oxide synthase in fetuses of a mouse model of streptozotocin-induced diabetes

A role for islet neogenesis in curing diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials